Company Profile
Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma-derived therapies, oncology, vaccines, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Takecab/Vocinti, EOHILIA, Takhzyro, Advate, Elaprase, Replagal, Vpriv, Adynovate/Adynovi, Livtencity, ADZYNMA, Gammagard Liquid/Kiovig, Hyqvia, Cuvitru, Flexbumin, Adcetris, Leuplin/Enantone, Ninlaro, Iclusig, FRUZAQLA, Alunbrig, vyvanse/elvanse, Trintellix, and QDENGA brands. It has licensing and collaboration for the development and commercialization of products with Arrowhead Pharmaceuticals, Cour Pharmaceuticals, Engitix, Halozyme, Mirum Pharmaceuticals, Ucsd/Fortis Advisors, Zedira/Dr. Falk Pharma, Ac Immune, Acurastem, Anima Biotech, Biomarin, Denali Therapeutics, Luxna Biotech, Neurocrine Biosciences, Peptidream, Abbvie, Adimab, Ascentage Pharma, Crescendo Biologics, Exelixis, F-Star, Gsk, Heidelberg Pharma, Innovent Biologics, Keros Therapeutics, Kumquat Biosciences, Protagonist Therapeutics, Halozyme, Kamada, Johnson & Johnson/Momenta Pharmaceuticals, Previpharma, Novavax, Bridgene Biosciences, Charles River Laboratories, Iambic Therapeutics, Ipsen, Km Biologics, Massachusetts Institute Of Technology, and Nabla Bio. The company operates in Japan, the United States. Europe, Canada, Latin America, China, Asia, Russia/Commonwealth of Independent States, the Middle East, Oceania, and Africa. The company was founded in 1781 and is headquartered in Chuo, Japan.
Latest News
Hankook iON Race Handles Tokyo's Day-to-Night Transition Across Two Races
Russell Reynolds Associates Announces Nick Fletcher as Australia Country Leader
Earnings To Watch: First Commonwealth Financial (FCF) Reports Q2 Results Tomorrow
Oil slips 4% after US, Iran pause fighting over weekend
This Quantum Stock Is a Key Nvidia Partner and Looks Like a Buy Near a 52-Week Low
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| Website | https://www.takeda.com |
| Audit Risk | 1 |
| Board Risk | 1 |
| Overall Risk | 1 |
| Market Cap | 9.21T |
| Forward P/E | 41.09 |
| Dividend Rate | 204 |
| Dividend Yield | 3.61% |
| Trailing Annual Div. Rate | 200 |
| Trailing Annual Div. Yield | 3.54% |
| Trailing EPS | -96.58 |
| Forward EPS | 140.39 |
| Book Value | 4,702.66 |
| Price-to-Book | 1.23 |
| Enterprise-to-Revenue | 3.06 |
| Enterprise-to-EBITDA | 11.17 |
| Ex-Dividend Date | 09/29/2026 |
| Earnings Date | 07/30/2026 |
| Earnings Call Date | |
| Revenue Average | 1.15T |
| Revenue Low | 1.10T |
| Revenue High | 1.21T |